Top

Published in:

Open Access 01-12-2019 | Prostate Cancer | Cancer-induced Musculoskeletal Diseases (E Keller and J Sterling, Section Editors)

Bone Health in Men with Prostate Cancer: Review Article

Authors: Salma A M El Badri, Abdulazeez Salawu, Janet E Brown

Published in: Current Osteoporosis Reports | Issue 6/2019

Abstract

Purpose of Review

The improvement in prostate cancer survival over time, even in those with advanced disease, has led to an increasing recognition of the impact of prostate cancer and its treatment on bone health. Cancer treatment–induced bone loss (CTIBL) is a well-recognized entity but greater awareness of the risks associated with CTIBL and its treatment is required.

Recent Findings

The principal culprit in causing CTIBL is hormonal ablation induced by prostate cancer treatment, including several new agents which have been developed in recent years which significantly improve survival, but may cause CTIBL. This review discusses the impact of prostate cancer and its treatment on bone health, including published evidence on the underlying pathophysiology, assessment of bone health, and strategies for prevention and treatment.

Summary

It is important to recognize the potential cumulative impact of systemic prostate cancer treatments on bone health.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Cancer Research UK. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer#heading-Two. 25 June 2019.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551.CrossRefPubMed

Taitt HE. Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location. Am J Mens Health. 2018;12(6):1807–23. https://doi.org/10.1177/1557988318798279.CrossRefPubMedPubMedCentral

Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011;12(5):451–9. https://doi.org/10.1016/S1470-2045(11)70063-8.CrossRefPubMed

Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360(24):2516–27. https://doi.org/10.1056/NEJMoa0810095.CrossRefPubMed

Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003;21(21):3972–8. https://doi.org/10.1200/JCO.2003.11.023.CrossRefPubMed

Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368(14):1314–25. https://doi.org/10.1056/NEJMoa1212299.CrossRefPubMedPubMedCentral

Wu CT, Yang YH, Chen PC, Chen MF, Chen WC. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients. Osteoporos Int. 2015;26(9):2281–90. https://doi.org/10.1007/s00198-015-3135-9.CrossRefPubMed

10.

Wang A, Obertova Z, Brown C, Karunasinghe N, Bishop K, Ferguson L, et al. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand. BMC Cancer. 2015;15:837. https://doi.org/10.1186/s12885-015-1843-3.CrossRefPubMedPubMedCentral

11.

Nguyen C, Lairson DR, Swartz MD, Du XL. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer. Pharmacotherapy. 2018;38(10):999–1009. https://doi.org/10.1002/phar.2168.CrossRefPubMed

12.

Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol. 2006;175(1):136–9; discussion 9. https://doi.org/10.1016/S0022-5347(05)00033-9.CrossRefPubMed

13.

Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154–64. https://doi.org/10.1056/NEJMoa041943.CrossRefPubMed

14.

Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31(5):578–83.CrossRefPubMed

15.

Hussain SA, Weston R, Stephenson RN, George E, Parr NJ. Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int. 2003;92(7):690–4.CrossRefPubMed

16.

Shao YH, Moore DF, Shih W, Lin Y, Jang TL, Lu-Yao GL. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int. 2013;111(5):745–52. https://doi.org/10.1111/j.1464-410X.2012.11758.x.CrossRefPubMedPubMedCentral

17.

Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168(3):1005–7. https://doi.org/10.1097/01.ju.0000024395.86788.cc.CrossRefPubMed

18.

Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8:136. https://doi.org/10.1007/s11657-013-0136-1.CrossRefPubMedPubMedCentral

19.

National Institute for Health and Care Excellence (NICE). Prostate cancer: diagnosis and management NICE guideline [NG131]. https://www.nice.org.uk/guidance/ng131. 14 August 2019.

20.

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017;71(4):618–29. https://doi.org/10.1016/j.eururo.2016.08.003.CrossRefPubMed

21.

Saad F, Ivanescu C, Phung D, Loriot Y, Abhyankar S, Beer TM, et al. Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials. Prostate Cancer Prostatic Dis. 2017;20(1):110–6. https://doi.org/10.1038/pcan.2016.62.CrossRefPubMedPubMedCentral

22.

Vignani F, Bertaglia V, Buttigliero C, Tucci M, Scagliotti GV, Di Maio M. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. Cancer Treat Rev. 2016;44:61–73. https://doi.org/10.1016/j.ctrv.2016.02.002.CrossRefPubMed

23.

Park SH, Keller ET, Shiozawa Y. Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int. 2018;102(2):152–62. https://doi.org/10.1007/s00223-017-0350-8.CrossRefPubMed

24.

Sottnik JL, Keller ET. Understanding and targeting osteoclastic activity in prostate cancer bone metastases. Curr Mol Med. 2013;13(4):626–39.CrossRefPubMedPubMedCentral

25.

Mohamad NV, Soelaiman IN, Chin KY. A concise review of testosterone and bone health. Clin Interv Aging. 2016;11:1317–24. https://doi.org/10.2147/CIA.S115472.CrossRefPubMedPubMedCentral

26.

Almeida M, Laurent MR, Dubois V, Claessens F, O'Brien CA, Bouillon R, et al. Estrogens and Androgens in Skeletal Physiology and Pathophysiology. Physiol Rev. 2017;97(1):135–87. https://doi.org/10.1152/physrev.00033.2015.CrossRefPubMed

27.

Vanderschueren D, Laurent MR, Claessens F, Gielen E, Lagerquist MK, Vandenput L, et al. Sex steroid actions in male bone. Endocr Rev. 2014;35(6):906–60. https://doi.org/10.1210/er.2014-1024.CrossRefPubMedPubMedCentral

28.

Wu J, Henning P, Sjogren K, Koskela A, Tuukkanen J, Moverare-Skrtic S, et al. The androgen receptor is required for maintenance of bone mass in adult male mice. Mol Cell Endocrinol. 2019;479:159–69. https://doi.org/10.1016/j.mce.2018.10.008.CrossRefPubMed

29.

Todenhofer T, Stenzl A, Hofbauer LC, Rachner TD. Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies. Int J Endocrinol. 2015;2015:838202. https://doi.org/10.1155/2015/838202.CrossRefPubMedPubMedCentral

30.

Khosla S. New Insights Into Androgen and Estrogen Receptor Regulation of the Male Skeleton. J Bone Miner Res. 2015;30(7):1134–7. https://doi.org/10.1002/jbmr.2529.CrossRefPubMed

31.

Drake MT, Khosla S. Male osteoporosis. Endocrinol Metab Clin N Am. 2012;41(3):629–41. https://doi.org/10.1016/j.ecl.2012.05.001.CrossRef

32.

Argoud T, Boutroy S, Claustrat B, Chapurlat R, Szulc P. Association between sex steroid levels and bone microarchitecture in men: the STRAMBO study. J Clin Endocrinol Metab. 2014;99(4):1400–10. https://doi.org/10.1210/jc.2013-3233.CrossRefPubMed

33.

Piot A, Chapurlat RD, Claustrat B, Szulc P. Relationship Between Sex Steroids and Deterioration of Bone Microarchitecture in Older Men: The Prospective STRAMBO Study. J Bone Miner Res. 2019. https://doi.org/10.1002/jbmr.3746.CrossRefPubMed

34.

Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90(12):6410–7. https://doi.org/10.1210/jc.2005-0183.CrossRefPubMed

35.

Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology. 2001;57(1):127–32.CrossRefPubMed

36.

den Uyl D, Bultink IE, Lems WF. Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep. 2011;13(3):233–40. https://doi.org/10.1007/s11926-011-0173-y.CrossRef

37.

Dorff TB, Crawford ED. Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer. Ann Oncol. 2013;24(1):31–8. https://doi.org/10.1093/annonc/mds216.CrossRefPubMed

38.

Auchus RJ, Yu MK, Nguyen S, Mundle SD. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. Oncologist. 2014;19(12):1231–40. https://doi.org/10.1634/theoncologist.2014-0167.CrossRefPubMedPubMedCentral

39.

•• Hoffman-Censits J, Kelly WK. Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer. Clin Cancer Res. 2013;19(6):1335–9. https://doi.org/10.1158/1078-0432.CCR-12-2910 Enzalutamide is a novel therapy that very potently blocks the androgen signaling pathway, which is unregulated during the development of CRPC. This paper reviews the preclinical studies along with the pivotal trials that led to its approval by the U.S. Food and Drug Administration (FDA) in September 2012.CrossRefPubMed

40.

Merseburger AS, Haas GP, von Klot CA. An update on enzalutamide in the treatment of prostate cancer. Ther Adv Urol. 2015;7(1):9–21. https://doi.org/10.1177/1756287214555336.CrossRefPubMedPubMedCentral

41.

•• Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, Ryan CJ, et al. Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. Clin Cancer Res. 2017;23(14):3544–51. https://doi.org/10.1158/1078-0432.CCR-16-2509This paper evaluates the efficacy of apalutamide before or after treatment with abiraterone acetate and prednisone in patients with progressive metastatic castration-resistant prostate cancer. Apalutamide was safe, well tolerated, and demonstrated clinical activity in mCRPC, with 80% of AAP-naïve and 43% of post-AAP patients, remaining on treatment for 6 months or longer. CrossRefPubMedPubMedCentral

42.

Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20(7):1185–94. https://doi.org/10.1359/JBMR.050304.CrossRefPubMed

43.

Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312(7041):1254–9. https://doi.org/10.1136/bmj.312.7041.1254.CrossRefPubMedPubMedCentral

44.

Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008;19(4):399–428. https://doi.org/10.1007/s00198-008-0560-z.CrossRefPubMedPubMedCentral

45.

International Society for Clinical Densitometry (ISCD). 2019 ISCD Official Positions – Adult. 2019. https://www.iscd.org/official-positions/2019-iscd-official-positions-adult/. Accessed 14 August 2019.

46.

Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9(8):1137–41. https://doi.org/10.1002/jbmr.5650090802.CrossRefPubMed

47.

Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001;286(22):2815–22. https://doi.org/10.1001/jama.286.22.2815.CrossRefPubMed

48.

Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int. 2011;22(9):2395–411. https://doi.org/10.1007/s00198-011-1713-z.CrossRefPubMed

49.

Kanis JA, Johansson H, Harvey NC, McCloskey EV. A brief history of FRAX. Arch Osteoporos. 2018;13(1):118. https://doi.org/10.1007/s11657-018-0510-0.CrossRefPubMedPubMedCentral

50.

Collins GS, Mallett S, Altman DG. Predicting risk of osteoporotic and hip fracture in the United Kingdom: prospective independent and external validation of QFractureScores. BMJ. 2011;342:d3651. https://doi.org/10.1136/bmj.d3651.CrossRefPubMedPubMedCentral

51.

Hippisley-Cox J, Coupland C, Brindle P. The performance of seven QPrediction risk scores in an independent external sample of patients from general practice: a validation study. BMJ Open. 2014;4(8):e005809. https://doi.org/10.1136/bmjopen-2014-005809.CrossRefPubMedPubMedCentral

52.

Salawu A, Handforth C, Brown J. Bone-Targeted Therapies in Prostate Cancer. In: Bolla M, Van Poppel H, editors. Management of Prostate Cancer: Springer International Publishing; 2017; 343–356

53.

Lassemillante AM, Skinner TL, Hooper JD, Prins JB, Wright ORL. Osteoporosis-Related Health Behaviors in Men With Prostate Cancer and Survivors: Exploring Osteoporosis Knowledge, Health Beliefs, and Self-Efficacy. Am J Mens Health. 2017;11(1):13–23. https://doi.org/10.1177/1557988315615956.CrossRefPubMed

54.

Nadler M, Alibhai S, Catton P, Catton C, To MJ, Jones JM. Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer. BJU Int. 2013;111(8):1301–9. https://doi.org/10.1111/j.1464-410X.2012.11777.x.CrossRefPubMed

55.

McKean H, Looker S, Hartmann LC, Hayman SR, Kaur JS, McWilliams RR, et al. Are cancer survivors/patients knowledgeable about osteoporosis? Results from a survey of 285 chemotherapy-treated cancer patients and their companions. J Nutr Educ Behav. 2008;40(3):144–8. https://doi.org/10.1016/j.jneb.2007.08.009.CrossRefPubMed

56.

Tripathy D, Durie BG, Mautner B, Ferenz KS, Moul JW. Awareness, concern, and communication between physicians and patients on bone health in cancer. Support Care Cancer. 2014;22(6):1601–10. https://doi.org/10.1007/s00520-014-2127-1.CrossRefPubMed

57.

Alibhai SM, Rahman S, Warde PR, Jewett MA, Jaffer T, Cheung AM. Prevention and management of osteoporosis in men receiving androgen deprivation therapy: a survey of urologists and radiation oncologists. Urology. 2006;68(1):126–31. https://doi.org/10.1016/j.urology.2006.01.054.CrossRefPubMed

58.

Damji AN, Bies K, Alibhai SM, Jones JM. Bone health management in men undergoing ADT: examining enablers and barriers to care. Osteoporos Int. 2015;26(3):951–9. https://doi.org/10.1007/s00198-014-2997-6.CrossRefPubMed

59.

•• Alibhai SMH, Breunis H, Timilshina N, Hamidi MS, Cheung AM, Tomlinson GA, et al. Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial. Cancer. 2018;124(6):1132–40. https://doi.org/10.1002/cncr.31171Educational strategies to improve bone health care appear feasible and are associated with improved BMD ordering in men receiving ADT. CrossRefPubMed

60.

des Bordes JKA, Suarez-Almazor ME, Volk RJ, Lu H, Edwards B, Lopez-Olivo MA. Online Educational Tool to Promote Bone Health in Cancer Survivors. J Health Commun. 2017;22(10):808–17. https://doi.org/10.1080/10810730.2017.1360415.CrossRefPubMed

61.

Agarwal MM, Khandelwal N, Mandal AK, Rana SV, Gupta V, Chandra Mohan V, et al. Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy. Cancer. 2005;103(10):2042–52. https://doi.org/10.1002/cncr.21047.CrossRefPubMed

62.

Owen PJ, Daly RM, Livingston PM, Fraser SF. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update. Prostate Cancer Prostatic Dis. 2017;20(2):137–45. https://doi.org/10.1038/pcan.2016.69.CrossRefPubMedPubMedCentral

63.

Lee CE, Leslie WD, Czaykowski P, Gingerich J, Geirnaert M, Lau YK. A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy. Curr Oncol. 2011;18(4):e163–72. https://doi.org/10.3747/co.v18i4.746.CrossRefPubMedPubMedCentral

64.

Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Med J Aust. 2011;194(6):301–6.CrossRefPubMed

65.

Nelson SM, Batai K, Ahaghotu C, Agurs-Collins T, Kittles RA. Association between Serum 25-Hydroxy-Vitamin D and Aggressive Prostate Cancer in African American Men. Nutrients. 2016;9(1). https://doi.org/10.3390/nu9010012.CrossRefPubMedCentral

66.

Batai K, Murphy AB, Ruden M, Newsome J, Shah E, Dixon MA, et al. Race and BMI modify associations of calcium and vitamin D intake with prostate cancer. BMC Cancer. 2017;17(1):64. https://doi.org/10.1186/s12885-017-3060-8.CrossRefPubMedPubMedCentral

67.

Capiod T, Barry Delongchamps N, Pigat N, Souberbielle JC, Goffin V. Do dietary calcium and vitamin D matter in men with prostate cancer? Nat Rev Urol. 2018;15(7):453–61. https://doi.org/10.1038/s41585-018-0015-z.CrossRefPubMed

68.

Datta M, Schwartz GG. Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review. Oncologist. 2012;17(9):1171–9. https://doi.org/10.1634/theoncologist.2012-0051.CrossRefPubMedPubMedCentral

69.

Owen PJ, Daly RM, Dalla Via J, Mundell NL, Livingston PM, Rantalainen T, et al. The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer. J Cachexia Sarcopenia Muscle. 2019. https://doi.org/10.1002/jcsm.12446.CrossRefPubMedPubMedCentral

70.

Grossmann M, Cheung AS, Zajac JD. Androgens and prostate cancer; pathogenesis and deprivation therapy. Best Pract Res Clin Endocrinol Metab. 2013;27(4):603–16. https://doi.org/10.1016/j.beem.2013.05.001.CrossRefPubMed

71.

Martone AM, Marzetti E, Calvani R, Picca A, Tosato M, Santoro L, et al. Exercise and Protein Intake: A Synergistic Approach against Sarcopenia. Biomed Res Int. 2017;2017:2672435. https://doi.org/10.1155/2017/2672435.CrossRefPubMedPubMedCentral

72.

Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345(13):948–55. https://doi.org/10.1056/NEJMoa010845.CrossRefPubMed

73.

Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007;25(9):1038–42. https://doi.org/10.1200/JCO.2006.07.3361.CrossRefPubMed

74.

Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, et al. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol. 2009;182(5):2257–64. https://doi.org/10.1016/j.juro.2009.07.046.CrossRefPubMed

75.

Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169(6):2008–12. https://doi.org/10.1097/01.ju.0000063820.94994.95.CrossRefPubMed

76.

Magno C, Anastasi G, Morabito N, Gaudio A, Maisano D, Franchina F, et al. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate. Eur Urol. 2005;47(5):575–80; discussion 80-1. https://doi.org/10.1016/j.eururo.2005.01.012.CrossRefPubMed

77.

Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol. 2006;176(3):972–8; discussion 8. https://doi.org/10.1016/j.juro.2006.04.078.CrossRefPubMed

78.

Ryan CW, Huo D, Bylow K, Demers LM, Stadler WM, Henderson TO, et al. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int. 2007;100(1):70–5. https://doi.org/10.1111/j.1464-410X.2007.06853.x.CrossRefPubMed

79.

Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL. Canadian Urology Research C. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. Eur Urol. 2013;63(5):927–35. https://doi.org/10.1016/j.eururo.2012.09.007.CrossRefPubMed

80.

Choo R, Lukka H, Cheung P, Corbett T, Briones-Urbina R, Vieth R, et al. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2013;85(5):1239–45. https://doi.org/10.1016/j.ijrobp.2012.11.007.CrossRefPubMed

81.

Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med. 2007;146(6):416–24. https://doi.org/10.7326/0003-4819-146-6-200703200-00006.CrossRefPubMed

82.

Greenspan SL, Nelson JB, Trump DL, Wagner JM, Miller ME, Perera S, et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol. 2008;26(27):4426–34. https://doi.org/10.1200/JCO.2007.15.1233.CrossRefPubMedPubMedCentral

83.

Rodrigues P, Hering FO, Bruna P, Meller A, Afonso Y. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study. Int J Urol. 2007;14(4):317–20. https://doi.org/10.1111/j.1442-2042.2006.01721.x.CrossRefPubMed

84.

Israeli RS, Rosenberg SJ, Saltzstein DR, Gottesman JE, Goldstein HR, Hull GW, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer. 2007;5(4):271–7. https://doi.org/10.3816/CGC.2007.n.003.CrossRefPubMed

85.

Kachnic LA, Pugh SL, Tai P, Smith M, Gore E, Shah AB, et al. RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients. Prostate Cancer Prostatic Dis. 2013;16(4):382–6. https://doi.org/10.1038/pcan.2013.35.CrossRefPubMedPubMedCentral

86.

Denham JW, Nowitz M, Joseph D, Duchesne G, Spry NA, Lamb DS, et al. Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer. BJU Int. 2014;114(3):344–53. https://doi.org/10.1111/bju.12497.CrossRefPubMed

87.

Taxel P, Dowsett R, Richter L, Fall P, Klepinger A, Albertsen P. Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Int. 2010;106(10):1473–6. https://doi.org/10.1111/j.1464-410X.2010.09329.x.CrossRefPubMed

88.

Casey R, Gesztesi Z, Rochford J. Long term zoledronic acid during androgen blockade for prostate cancer. Can J Urol. 2010;17(3):5170–7.PubMed

89.

Kapoor A, Gupta A, Desai N, Ahn H. Effect of zoledronic Acid on bone mineral density in men with prostate cancer receiving gonadotropin-releasing hormone analog. Prostate Cancer. 2011;2011:176164. https://doi.org/10.1155/2011/176164.CrossRefPubMed

90.

Serpa Neto A, Tobias-Machado M, Esteves MA, Senra MD, Wroclawski ML, Fonseca FL, et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2012;15(1):36–44. https://doi.org/10.1038/pcan.2011.4.CrossRefPubMed

91.

Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745–55. https://doi.org/10.1056/NEJMoa0809003.CrossRefPubMedPubMedCentral

92.

Doria C, Leali PT, Solla F, Maestretti G, Balsano M, Scarpa RM. Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study. Clin Cases Miner Bone Metab. 2016;13(3):195–9. https://doi.org/10.11138/ccmbm/2016.13.3.195.CrossRefPubMed

93.

Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89(8):3841–6. https://doi.org/10.1210/jc.2003-032058.CrossRefPubMed

94.

Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2013;189(1 Suppl):S45–50. https://doi.org/10.1016/j.juro.2012.11.016.CrossRefPubMed

Title: Bone Health in Men with Prostate Cancer: Review Article
Authors: Salma A M El Badri
Abdulazeez Salawu
Janet E Brown
Publication date: 01-12-2019
Publisher: Springer US
Keywords: Prostate Cancer
Prostate Cancer
Osteoporosis
Osteoporosis
Androgens
Published in: Current Osteoporosis Reports / Issue 6/2019
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-019-00536-8

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Bone Health in Men with Prostate Cancer: Review Article

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 6/2019

Aging and Mechanoadaptive Responsiveness of Bone

Population-Based Osteoporosis Primary Prevention and Screening for Quality of Care in Osteoporosis, Current Osteoporosis Reports

Bone Marrow Adipose Tissue Quantification by Imaging

Pragmatic Clinical Trials in Osteoporosis

Update on Menopausal Hormone Therapy for Fracture Prevention

Insulin Signaling in Bone Marrow Adipocytes